Accustem Sciences (ACUT) Receivables - Other (2021 - 2022)
Accustem Sciences (ACUT) posted quarterly Receivables - Other of -$33424.0 for Q4 2022, up 70.15% year-over-year from -$19643.5 in Q4 2021, and down 128.53% quarter-over-quarter from $117139.0 in Q1 2022.
Accustem Sciences (ACUT) Receivables - Other (2021 - 2022) Analysis & Trends
Accustem Sciences (ACUT) has reported Receivables - Other for 2 consecutive years, with -$33424.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Receivables - Other rose 70.15% year-over-year to -$33424.0; the TTM figure through Dec 2022 stood at -$76176.0 (up 55.96% YoY), while the FY2022 annual figure was $48609.0, down 96.88% from the prior year.
- Receivables - Other eased to -$33424.0 in Q4 2022 per ACUT's latest filing, from $117139.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $117139.0 in Q1 2022 and bottomed at -$111983.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -33,424.00 |
| Dec 31, 2022 | -33,424.00 |
| Mar 31, 2022 | 117,139.00 |
| Mar 31, 2022 | 117,139.00 |
| Dec 31, 2021 | -111,983.00 |
| Dec 31, 2021 | -111,983.00 |
| Sep 30, 2021 | -47,908.00 |
| Sep 30, 2021 | -47,908.00 |
| Jun 30, 2021 | -6,201.00 |
| Jun 30, 2021 | -6,201.00 |
| Mar 31, 2021 | -6,874.00 |
| Mar 31, 2021 | -6,874.00 |